Axonics (Nasdaq:AXNX) announced today that a jury unanimously ruled in its favor in a patent spat with (NYSE: MDT).

A federal jury in California has found that Axonics’ neurostimulators and electric leads for treating incontinence do not run ...

The Court for the Central District of California has sided with Axonics finding the company did not breach Medtronic’s ...

Meanwhile, Boston Scientific is still waiting for antitrust regulators to conclude their review of its proposal to buy ...

Axonics, Inc. (AXNX) comes out victorious in a patent trial against Medtronic (MDT), as the jury rules in its favor, awarding ...

A jury unanimously found that Axonics did not infringe any of the three patents-in-suit brought against the company by Medtronic in a patent infringement lawsuit in the U.S. District Court for the ...

Axonics, Inc. (Nasdaq: AXNX) today announced that the jury has returned a unanimous verdict in the patent infringement lawsuit brought by Medtronic against Axonics in U.S. District Court for the ...

Learn the story of how Medtronic, one of the world's largest medical equipment and therapies suppliers, generates money and ...

The past month has been quite encouraging for Medtronic MDT investors. Solid first-quarter fiscal 2025 organic growth performance and several strategic initiatives to revamp the bottom line, including ...

Advanced materials are key to next-gen sensors, improving sensitivity and durability for critical applications in healthcare ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

New over-the-counter sensors, an Abbott-Medtronic partnership and Roche’s first CGM are among diabetes technology’s top stories so far in 2024. Check out MedTech Dive’s roundup of the latest news.